NCT02156336 - Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 8, 2017

Study Completion Date

February 8, 2017

Conditions

Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

Ranolazine

Oral administration, BID; for a maximum of 51 days.

DRUG

Placebo

Oral administration, BID; for a maximum of 51 days.

Trial Locations (3)

Cardiology Associates, Fairhope

Cardiovascular Institute of the South, Houma

Cardiovascular Institute of the South, Lafayette